EMA Authorised: Jakavi (ruxolitinib phosphate) — Novartis Europharm Limited

View source ↗

Summary

Jakavi (ruxolitinib phosphate) has been authorised in the EU with indications for polycythemia vera and graft-versus-host disease. The decision was issued to No…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Polycythemia Vera

Drugs mentioned

• Jakavi (ruxolitinib)

Snippet

Status: Authorised. Therapeutic area: Myeloproliferative Disorders;Polycythemia Vera;Graft vs Host Disease. MAH: Novartis Europharm Limited. Decision date: 10/11/2025